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Abstract
Background: Mesenchymal stem cells (MSCs) are an attractive source of adult stem cells for therapeutic application in 
clinical study. Genetic modification of MSCs with beneficial genes makes them more effective for therapeutic use. 
However, it is difficult to transduce genes into MSCs by common transfection methods, especially nonviral methods. In 
this study, we applied microporation technology as a novel electroporation technique to introduce enhanced green 
fluorescent protein (EGFP) and brain-derived neurotropfic factor (BDNF) plasmid DNA into human umbilical cord 
blood-derived MSCs (hUCB-MSCs) with significant efficiency, and investigated the stem cell potentiality of engineered 
MSCs through their phenotypes, proliferative capacity, ability to differentiate into multiple lineages, and migration 
ability towards malignant glioma cells.
Results: Using microporation with EGFP as a reporter gene, hUCB-MSCs were transfected with higher efficiency (83%) 
and only minimal cell damage than when conventional liposome-based reagent (<20%) or established electroporation 
methods were used (30-40%). More importantly, microporation did not affect the immunophenotype of hUCB-MSCs, 
their proliferation activity, ability to differentiate into mesodermal and ectodermal lineages, or migration ability towards 
cancer cells. In addition, the BDNF gene could be successfully transfected into hUCB-MSCs, and BDNF expression 
remained fairly constant for the first 2 weeks in vitro and in vivo. Moreover, microporation of BDNF gene into hUCB-
MSCs promoted their in vitro differentiation into neural cells.
Conclusion: Taken together, the present data demonstrates the value of microporation as an efficient means of 
transfection of MSCs without changing their multiple properties. Gene delivery by microporation may enhance the 
feasibility of transgenic stem cell therapy.
Background
Stem cells are highly attractive and valuable candidates
for biomedical applications including the development of
cell and gene therapy. Of the various stem cells, mesen-
chymal stem cells (MSCs) show a particular potential for
clinical use because of their high proliferative capacity,
ability to differentiate into multiple lineages [1-3], and
ability to migrate into injured organs [4,5] and cancers
[6,7]. Moreover, MSCs are not immunogenic, and so do
not elicit a proliferative response of allogeneic lympho-
cytes in vitro [8]. Therefore, MSCs have become a major
focus of research for potential therapeutic applications
for various diseases.
In recent years, efforts have been made to improve the
therapeutic efficacy of MSCs through combination
approaches using MSCs and genes. Additionally, a new
therapeutic strategy has been developed that uses MSCs
for the targeted delivery and local production of biologic
agents in tumors [6,9]. Viruses are commonly used as
vehicles to deliver transgenes into stem cells that can be
available to effectively infect dividing or nondividing
cells. Integrating virus, including retrovirus or lentivirus,
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Page 2 of 13can insert their viral DNA into the host genomic DNA,
which allows for stable genetic modification for the life of
the host cells. So, they are very efficient for long-term
gene expression [10-12]. Alternatively, nonintegrating
viruses, including adenovirus or herpes saimirii virus, are
preferentially used to obtain the expression of a therapeu-
tic gene for a short time, although these viruses are less
efficient at transferring genes into cells [13]. Overall,
virus systems permit efficient gene delivery into cells;
however, they have safety concerns that are critical when
considering clinical applications [14]. Furthermore, their
use sometimes causes significant changes in the charac-
teristics of genetically modified cells [15].
To overcome these problems, nonviral methods are
receiving increasing attention because they have several
potential advantages over recombinant viruses. They are
noninfectious, relatively nonimmunogenic, have low
acute toxicity, can accommodate large DNA plasmids,
and can be produced simply on a large scale [16]. There
are various types of nonviral systems used for gene trans-
fer, such as the liposome-based method [17], electropora-
tion [18], and calcium phosphate techniques [19].
Electroporation, which permeabilizes the cell membrane
by an electric pulse, has been widely used [20-22]. How-
ever, these methods are limited by their low gene transfer
efficiency compared with viruses and their transient gene
expression [16]. In addition, high cell mortality is still a
problem in electroporation. Low levels of gene transfer
continue to be a major obstacle in the use of nonviral sys-
tems because gene delivery and efficient gene transfer are
prerequisites for the development of MSC therapy using
various beneficial genes in clinical trials.
In contrast to conventional electroporation methods,
microporation is a unique electroporation technology
that uses a pipette tip as an electroporation space and a
capillary type of electric chamber instead of a cuvette,
which counteracts the harmful effects of cuvette-based
electroporation gene transfer techniques such as pH vari-
ation, increasing in temperature, and metal ion genera-
tion.
The present study reports a nonviral, high-efficiency
method of transfecting human umbilical cord blood-
derived MSCs (hUCB-MSCs) using the new electropora-
tion-based gene transfer technique of microporation.
Microporation was utilized to introduce enhanced green
fluorescent protein (EGFP) as a reporter gene and a plas-
mid expressing the gene of interest, brain-derived neu-
rotrophic factor (BDNF), into hUCB-MSCs with
significant efficiency, and investigated the stem cell
potentiality of engineered hUCB-MSCs through their
phenotypes, proliferative capacity, ability to differentiate
into multiple lineages, and migration ability towards
malignant glioma cells.
Results
Microporation of hUCB-MSCs Induces High Transient 
Transfection Efficiency
To investigate the gene transfection efficiency of the
microporation technique, hUCB-MSCs were transfected
with EGFP-N1 plasmid (pEGFP-N1) by various transfec-
tion methods including liposome-based reagent, estab-
lished electroporations, and microporation. For
electroporation, 2 × 105 cells were resuspended in phos-
phate buffered saline (PBS) or resuspension buffer, mixed
with 2 μg DNA and electroporated as described previ-
ously [23,24]. For microporation, 2 μg DNA was mixed
with resuspension buffer. Then, 2 × 105 cells were elec-
troporated with a preoptimized square pulse condition
(1600 V, 20 ms, 1 pulse). Figure 1A showed the brightfield
and green fluorescence images of cells. In addition, the
percentage of EGFP-positive cells 24 hr after transfection
was determined by fluorescence-activated cell sorting
(FACS) analysis (Figure 1B). The percentage of EGFP-
positive cells was 30%-50% for the established electropo-
rators, Nucleofector®, ECM 830 or MicroPulser™. By com-
parison, the MicroPorator™ microporation device
achieved a transfection efficiency of 83% under the con-
ditions tested. In addition, microporation-based transfec-
tion of hUCB-MSCs showed a higher cell survival rate
compared with other systems (Figure 1C). Although
Gene Porter2-based transfection of hUCB-MSCs demon-
strated a high cell survival rate, EGFP expression was too
low (< 20%).
We further examined the survival of microporated cells
during 15 days culture of actively dividing cells. Cell via-
bility was about 80% 2 days after microporation, and via-
bility was sustained for more than 15 days (Figure 2A). To
increase the application performance of microporation,
transfection efficacies were examined in different hUCB-
MSCs from different donors. Similar transfection effi-
ciencies were obtained (Figure 2B).
To assess the stability of the microporation-based
transfection, the time course and the level of EGFP
expression were determined over a period of 3 weeks
under conditions of restrained cell division (a-minimal
essential medium (MEM) containing 2% fetal bovine
serum (FBS) and no passaging). Fluorescence images and
FACS analysis at different time points after transfection
revealed that EGFP expression was sustained at high lev-
els (>60%) for the first 10 days and began to decline after
2 weeks (Figure 3A). We also examined the EGFP expres-
sion level in actively dividing cells under standard culture
conditions (a-MEM containing 10% FBS and subcultur-
ing at 90% confluency). Similarly, EGFP expression was
sustained at high levels (>60%) for the first 10 days and
began to decline after 15 days (Figure 3B). By compari-
son, EGFP expression was decreased markedly 10 days
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level was weak (Figure 4). These results indicate that
transfection by microporation is an efficient way of
obtaining successful gene delivery into MSCs.
Multiple Stem Cell Traits of EGFP-expressing hUCB-MSCs by 
Microporation
To investigate the stem cell potentiality of hUCB-MSCs
according to transfection by Microporatot™, cell prolifer-
ative capacity was evaluated by a trypan blue exclusion
assay. Both non-transfected hUCB-MSCs and hUCB-
MSCs transfected with pEGFP-N1 grew in a similar fash-
ion in a time-dependent manner (Figure 5A). The in vitro
culture of cells appeared to be unaffected by transfection
using the microporation.
To further study stem cell potentiality, the expression of
MSC-related cell surface antigens was evaluated by flow
cytometry (Figure 5B). Like hUCB-MSCs, transfected
hUCB-MSCs were strongly positive for the CD29, CD44,
CD73, and CD90 markers. However, both cells stained
negatively for HLA-class II (HLA-DR) and the
hematopoietic marker CD34.
The ability to differentiate into a variety of cell types is
an important characteristic of MSCs [2,3]. To evaluate
the influence of microporation on multilineage differenti-
ation of hUCB-MSCs, hUCB-MSCs and hUCB-MSCs
transfected with pEGFP-N1 by microporation were
induced into osteogenic and adipogenic differentiation.
Both cells showed similar differentiation into the osteo-
genic and adipogenic lineages when grown in culture
with the appropriate differentiation medium. Osteogenic
differentiation was determined by von Kossa staining
(Figure 5C). Adipogenic differentiation was apparent in
the cells by cellular accumulation of lipid-rich vacuoles
that were stained with Oil Red O (Figure 5D). EGFP
expression was maintained in hUCB-MSCs during the
osteoinductive conditions (Figure 5E).
Figure 1 Transfection efficiency of hUCB-MSCs. (A) pEGFP-N1 vector was transfected into hUCB-MSCs by the established electroporators Nucleo-
fector®, ECM 830, MicroPulser™, and a novel electroporator, MicroPorator™, or by a liposome-based reagent, Gene Porter2. After 24 hr, EGFP expression 
was analyzed using phase contrast and fluorescence microscopy. (B) Transient expression of EGFP was assessed by FACS analysis. (C) After transfection, 
cells were cultured for additional 48 hr and analyzed for viability by the MTS assay. The data are expressed as the mean ± SEM; n = 3. Scale bar = 200 μm.
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characteristic of MSCs. Recent studies have indicated
that MSCs exhibit potent tropism for malignant glioma
cells [7,9]. To test this in hUCB-MSCs transfected with
pEGFP-N1 by microporation, in vitro migration assays
using Transwell plates were conducted. Conditioned
medium (CM) from normal human astrocytes was used
as a control to mimic the normal brain milieu. Only a few
cells migrated toward serum-free medium (SFM) and
CM from normal human astrocytes, whereas the migra-
tion of cells was significantly stimulated by CM from the
human glioma cell line U-87MG compared with CM
from astrocytes. We also confirmed that transfected
hUCB-MSCs migrated towards CM from U-87MG cells
in a similar pattern to hUCB-MSCs (Figure 6). In addi-
tion, the expression of EGFP was observed in migrated
hUCB-MSCs. Thus, the migratory ability of hUCB-MSCs
was not affected by microporation.
Characterization of BDNF-expressing hUCB-MSCs by 
Microporation
To investigate the potential for application of micropo-
rated hUCB-MSCs for cell therapy, the gene of interest
harbored in a BDNF expression plasmid (pEGFP-BDNF)
was transfected into hUCB-MSCs and the transgene
expression and its effects for promoting in vitro differen-
tiation of hUCB-MSCs into neural cells were examined.
BDNF regulates the survival, development, and function
of neurons, and is important for differentiation of neural
precursor cells [25,26]. Our previous report demon-
strated that BDNF stimulates in vitro differentiation of
MSCs into neural cells [27]. In addition, MSCs genetically
modified with the BDNF gene effectively promote axonal
regeneration in transected adult rat spinal cord [28].
Therefore, if hUCB-MSCs could be successfully modified
with BDNF gene by microporation, it would be a valuable
cell source for the treatment of neurological disease.
Figure 2 Transfection efficiency of hUCB-MSCs from different donors. (A) After microporation, cells survival was analyzed by the MTS assay at 
different time points under standard culture conditions (a-MEM containing 10% FBS and subculturing at 90% confluency). (B) pEGFP-N1 vector was 
transfected into different hUCB-MSCs from different donors by microporation. After 24 hr, the expression of EGFP was analyzed using phase contrast 
and fluorescence microscopy. Transient expression of EGFP was assessed by FACS analysis. The data are expressed as the mean ± SEM; n = 3. Scale 
bar = 200 μm.
Lim et al. BMC Biotechnology 2010, 10:38
http://www.biomedcentral.com/1472-6750/10/38
Page 5 of 13Enzyme-linked immunosorbant assay (ELISA) analysis
at different time points after transfection revealed that
the concentration of secreted BDNF in vitro remained
fairly constant for 14 days and then began to decline in
transfected hUCB-MSCs (Figure 7A, left panel). Addi-
tionally, immunocytochemical analysis showed strong
staining for BDNF in the transfected cells (Figure 7A,
right panel). The levels of BDNF protein and its longevity
in vivo were quantitatively measured. ELISA analysis on
different days after transplantation of cells into rat brain
revealed that the BDNF protein expressed in brain tissues
was detectable on day 1, peaked on day 7, and persisted
for two weeks. In control groups, expression levels of
BDNF were low throughout the experimental period
(Figure 7B, left panel). In addition, immunohistochemical
analysis 3 days after transplantation showed strong stain-
ing for BDNF in the injection site or areas around the
injection site of BDNF-expressing hUCB-MSCs (Figure
7B, right panel).
To investigate the effect of BDNF in promoting in vitro
differentiation of hUCB-MSCs into neural cells, cell mor-
phology was observed when hUCB-MSCs were treated
with neural induction medium (NIM), with or without
transfection of BDNF expression plasmid by micropora-
tion Non-transfected or transfected hUCB-MSCs were
incubated overnight in preinduction medium containing
bFGF. Next, they were transferred to NIM, and then
maintained for up to 7 days. hUCB-MSCs transfected
with BDNF expression plasmid progressively assumed
neuronal morphological characteristics. The cytoplasm
in the flat hUCB-MSCs retracted toward the nucleus,
resembling a typical neuronal soma, and the process
became thinner because of continuous shrinkage of the
cell body. The morphological changes progressed to yield
network-like structures and many long processes. How-
ever, these morphological changes were weak for the
non-transfected hUCB-MSCs, and only a few cells
showed pyramidal or spherical cell bodies with multiple
processes (Figure 8A). In addition to their neural mor-
phological differentiation, the effects of BDNF were
investigated by Western blot analysis. In the proliferating
medium, MSCs highly expressed the intermediate fila-
ment protein nestin. But, the expression of nestin
decreased dramatically after induction. MSCs were nega-
Figure 3 Time-course analysis of EGFP expression in microporated hUCB-MSCs. (A) pEGFP-N1 (2 μg) was transfected into hUCB-MSCs by mi-
croporation. The expression of EGFP was analyzed using phase contrast and fluorescence microscopy at different time points after transfection. Per-
sistence of EGFP expression in hUCB-MSCs was analyzed by FACS analysis under conditions of restrained cell division (a-MEM containing 2% FBS and 
no passaging). EGFP expression was assessed at different time points after transfection. (B) Persistence of EGFP expression in microporated hUCB-
MSCs was analyzed by FACS analysis under standard culture conditions. EGFP expression was assessed at different time points after transfection. The 
data are expressed as the mean ± SEM; n = 3. Scale bar = 200 μm.
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ing neuron marker Tuj-1, the mature neuron marker
NeuN, GFAP typical of astrocytes, and the oligodendro-
cyte marker MBP. Conversely, expression of Tuj-1 and
NeuN increased significantly after neurogenic stimula-
tion in BDNF-transfected hUCB-MSCs. In addition,
expression of GFAP and MBP increased after induction
in transfected cells. However, these increases were mar-
ginal for those non-transfected cells treated with NIM
(Figure 8B).
Next, the neural differentiation-related molecules in
the hUCB-MSCs and BDNF-transfected hUCB-MSCs
were examined after neural induction. Mitogen-activated
protein kinases are expressed abundantly in the central
nervous system, and extracellular signal-regulated
kinases (ERKs) participate in various activity-dependent
processes, including neuronal maturation, survival, and
synaptic functions. The phosphorylation levels of Raf-1
and ERKs were dramatically increased in BDNF-trans-
fected hUCB-MSCs at 7 days of induction (Figure 8C).
Discussion
MSCs therapy using therapeutic transgene holds the
potential as a powerful means of disease treatment. For
example, MSCs genetically modified with the BDNF gene
effectively promote axonal regeneration in transected
adult rat spinal cord [28] and also protect against injury
in a cerebral ischemia model in adult rats [29]. MSCs
genetically modified with bone morphogenic protein-2
(BMP-2) gene show good results in treating bone defects,
and engineering MSCs with BMP-2 has recently been the
focus for research into the treatment of a variety of bone
defects [30,31].
Many advances have been achieved in the field of gene
transfer; however, some problems such as poor efficiency
and maintenance of cell characteristics remain. Transfec-
tion of hard-to-transfect cells, including primary neuron
cells, primary blood cells, and stem cells through com-
mon methods such as the use of a liposome-based
reagent or electroporation is problematic because of low
transfection efficiency and low cell survival rates.
Figure 4 Time-course analysis of EGFP expression in nucleofected hUCB-MSCs. pEGFP-N1 (2 μg) was transfected into hUCB-MSCs by nucleofec-
tion. The expression of EGFP was analyzed using phase contrast and fluorescence microscopy at different time points after transfection. Persistence 
of EGFP expression in hUCB-MSCs was analyzed by FACS analysis under conditions of restrained cell division (a-MEM containing 2% FBS and no pas-
saging). EGFP expression was assessed at different time points after transfection. The data are expressed as the mean ± SEM; n = 3. Scale bar = 200 μm.
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gene wherever and whenever they are treated, as well as
their cell characteristics. If MSCs can be successfully
modified, more potential cells will be available for use in
treatment. Therefore, technology and methodology that
enables efficient gene transfer is needed.
In this study, we obtained successful transfection effi-
ciency with only minimal cell damage by the micropora-
tion-based transfection with the EGFP reporter plasmid
in hUCB-MSCs. Moreover, a plasmid expressing the gene
of interest, BDNF, could be successfully transfected into
hUCB-MSCs, and in vitro and in vivo experiments
showed that BDNF expression remained fairly constant
for the first 2 weeks (Figures 1, 2, 3, 4 and 7). These
results show that gene delivery by microporaton is a safe
and efficient means for prolonged transgene expression.
Recently, Wang et al. [32] demonstrated that micropo-
ration allows a highly efficient transfection of human adi-
pose tissue-derived stem cells, without impairing their
stem cell properties. Their results echo our data that
transfection by microporation is an efficient way of
obtaining successful gene delivery into hUCB-MSCs.
More importantly, microporation of BDNF gene into
hUCB-MSCs presently promoted in vitro neural charac-
teristics (Figure 8). MSCs can differentiate into neurons
in vitro under special experimental conditions [33] and in
vivo after transplantation into the brain and spinal cord
[34,35]. In addition, transplanted MSCs promoted func-
tional improvement in a spinal cord injury rat model [35].
Our previous results demonstrated that BDNF stimulates
in vitro differentiation of MSCs into neural cells [27]. Fur-
thermore, engineered MSCs with the BDNF gene effec-
tively promote neural differentiation and also protect
against injury in transected spinal cord or ischemia ani-
mal models [27,28,35]. Therefore, microporation-based
successful genetic modification of hUCB-MSCs with
BDNF makes them potential candidates for the treatment
of neurological diseases.
Additionally, microporation-mediated transfection of
pEGFP-N1 into hUCB-MSCs and EGFP overexpression
did not affect the multiple potential of stem cells. This
Figure 5 Multiple stem cell traits of EGFP-expressing hUCB-MSCs. (A) hUCB-MSCs were transfected with the 2 μg of pEGFP-N1 by microporation. 
After microporation, cells were cultured for additional 24 hr and analyzed with the trypan blue exclusion assay from 1-7 days. (B) Cells were labeled 
with antibodies against the indicated antigens and they were then analyzed by flow cytometry. hUCB-MSCs were transfected with the 2 μg of pEGFP-
N1. After transfection, cells were allowed to differentiate under the specific induction medium. The accumulation of calcium-containing mineral de-
posits in the extracellular matrix and lipidic vacuoles were revealed by the (C) von Kossa staining method and (D) Oil Red O solution after 3 weeks. (E) 
EGFP expression was maintained in hUCB-MSCs during the osteoinductive conditions. The data are expressed as the mean ± SEM; n = 3. Scale bar (C) 
= 200 μm. Scale bar (D,E) = 100 μm.
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tion, proliferative activity, ability to differentiate into mul-
tiple lineages, and potent migration ability for malignant
glioma cells (Figures 5 and 6). Maintenance of these mul-
tiple properties of modified stem cells is critical for
improving their therapeutic potentials. Otherwise, stem
cells may not be effective in a combination therapy of
stem cells and therapeutic genes. Therefore, questions
regarding the efficacy of gene transfection as well as
safety and maintenance of multiple stem cell traits after
gene modification need to be answered in greater detail
for the effective utilization of stem cells in treating human
diseases.
This study has established a reliable and efficient
method for introducing a transgene into stem cells.
Transfection by the microporation method led to 83%
successful expression of transgene in hUCB-MSCs. In
addition, multiple stem cell traits of hUCB-MSCs were
unaffected by transfection. Successful genetic modifica-
tion of stem cells requires achieving efficient DNA trans-
fer into cells and maintaining their multiple cell
characteristics. Therefore, transfection by the micropora-
tion is an efficient way of obtaining successful gene deliv-
ery into MSCs and gene delivery by microporation may
enhance the feasibility of transgenic stem cell therapy.
Conclusion
Successful transfection efficiency was obtained with only
minimal cell damage by the microporation-based trans-
fection with the EGFP reporter plasmid in hUCB-MSCs
without changing their multiple properties. Moreover, a
plasmid expressing the gene of interest, BDNF, could be
successfully transfected into hUCB-MSCs. More impor-
tantly, microporation of BDNF gene into hUCB-MSCs
Figure 6 Migration capacity of EGFP-expressing hUCB-MSCs. (A) hUCB-MSCs were transfected with the 2 μg of pEGFP-N1. After transfection, the 
migration response of hUCB-MSCs to conditioned medium from U-87MG cells or normal astrocytes was determined using a Transwell plate. Cell mi-
gration was compared and evaluated after staining by taking photographs and (B) counting cells that had migrated. Serum free medium was used as 
a negative control and SDF-1 was used as a positive control. The number of cells that had migrated to the lower side of the filter was counted in five 
or six different microscopic fields under a light microscope. (C) The expression of EGFP was observed in migrated hUCB-MSCs. Nuclei were counter-
stained with DAPI (blue). Experiments were performed in triplicate. Scale bar = 200 μm.
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transfection by the microporation is an efficient way of
obtaining successful gene delivery into MSCs and gene
delivery by microporation may enhance the feasibility of
transgenic stem cell therapy.
Methods
Plasmid Construction
An EGFP expression vector, pEGFP-N1, was purchased
from Clontech BD Bioscience (Palo Alto, CA, USA).
BDNF cDNA was obtained using the Marathon cDNA
Amplification system (Clontech) and cloned in the
TOPO TA Cloning vector (Invitrogen, Carlsbad, CA,
USA) and the sequence was verified. Plasmid encoding
human BDNF was generated by polymerase chain reac-
tion (PCR) cloning into pEGFP-N1 using KpnI (5" prim-
ers) and NotI (3" primers) restriction sites, which was
designated pEGFP-BDNF.
hUCB-MSCs and Transfection
Human UCB samples were obtained with consent from
the mothers and were separated and maintained in accor-
dance with techniques as previously described [36]. Cells
were transfected with pEGFP-N1 or pEGFP-BDNF by
liposome-based reagent, Gene Porter2 (Gene Therapy
System, San Diego, CA, USA), established electropora-
tors; Nucleofector® (Amaxa, Cologne, Germany), ECM
830 (BTX Harvard Apparatus, Holliston, MA, USA),
MicroPulser™ (Bio-Rad, Huston, TX, USA) and a novel
electroporator (MicroPorator™, Digital Bio, Seoul, Korea).
For electroporation, cells were trypsinized and resus-
pended in PBS for electroporation with the ECM 830 or
in resuspension buffer for electroporation with the
MicroPulser™ and Nucleofector®. Then 2 × 105 cells were
used for each electroporation. Briefly, 2 μg DNA was
mixed in PBS and electroporated as described previously
[23,24]. For microporation, 2 μg DNA was mixed with 10
Figure 7 Time-course analysis of BDNF expressions in microporated hUCB-MSCs. (A, left panel) pEGFP-BDNF (2 μg) was transfected into hUCB-
MSCs by microporation. The concentration of secreted BDNF was determined using an ELISA assay under conditions of expanded cells (a-MEM con-
taining 10% FBS). (A, right panel) Cells were stained for BDNF 3 days after transfection. (B, left panel) For the quantification of BDNF levels and longevity 
of BDNF expression in vivo, brain tissues were homogenized at 1, 3, 7, 10, and 14 days (n = 3/each group) after treatment and then assessed by ELISA. 
(B, right panel) Tissues were stained for BDNF 3 days after transplantation. Nuclei were counterstained with Hematoxylin (blue). The data are expressed 
as the mean ± SEM; n = 3. Scale bar = 200 μm.
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rated with a pre-optimized square pulse condition (1600
V, 20 ms, 1 pulse). Electroporated cells were incubated in
500 μl α-MEM (Invitrogen) supplemented with 10% FBS
(Invitrogen) without antibiotics for 24 hr, and then the
medium was replaced with a medium containing antibi-
otics. To assay transient and sustained expression, the
hUCB-MSCs were isolated by incubation in 0.25%
trypsin and 1 mM EDTA (Invitrogen) and assayed by a
FACSCalibur flow cytometer (Becton Dickinson, Frank-
lin Lakes, NJ, USA) 24 hr after transfection for EGFP-
expressing cells. The results were analyzed by CellQuest
software (Becton Dickinson).
Assessment of Cell Viability
hUCB-MSCs were transfected with pEGFP-N1 by vari-
ous transfection. Medium was removed 24 hr after trans-
fection, and replaced with medium containing
antibiotics. Cells were analyzed for viability by CellTiter
96® aqueous non-radioactive cell proliferation assay (Pro-
mega, Madison, WI, USA) at different time points after
transfection. The assay tests cellular viability and mito-
chondrial function. Briefly, after transfection, MTS solu-
tion was added to each culture plate and plates were
incubated at 37°C for 3 hr. The absorbance of the forma-
zan product, which is considered to be directly propor-
tional to the number of living cells in the culture, was
measured at 490 nm using an ELISA plate reader.
Figure 8 Neurogenic characteristics of BDNF-expressing hUCB-MSCs. (A) phase-contrast microscopy analysis of hUCB-MSCs after 3 and 7 days 
incubation in NIM, with or without microporation-based pEGFP-BDNF transfection (2 μg). (B) Western blotting of hUCB-MSCs before and 3 days of 
incubation in NIM with or without pEGFP-BDNF transfection. The cell lysates were then subjected to SDS-polyacrylamide gel electrophoresis and 
Western blot analysis with anti-nestin, anti-Tuj-1, anti-NeuN, anti-GFAP, and anti-MBP antibodies. (C) Western blotting of hUCB-MSCs before and 3 and 
7 days of incubation in NIM with or without pEGFP-BDNF transfection. The cell lysates were then subjected to SDS-polyacrylamide gel electrophoresis 
and Western blot analysis with anti-phospho ERK, -phospho -Raf-1 antibodies. Equal amounts of total protein were confirmed by using an anti-β-actin 
antibody. The results shown here are from one of two independent experiments. Scale bar = 100 μm
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Adult male SD rats (6-8 weeks old; Charles River Labora-
tories, Wilmington, MA, USA) were used in accordance
with institutional guidelines under the approved proto-
cols. Cells were transfected with pEGFP-BDNF and
maintained further for 48 hr in α-MEM containing 10%
FBS. For the intracranial xenografts of hUCB-MSCs, ani-
mals were anesthetized with an intraperitoneal injection
of ketamine/xylazine and 3 × 105 cells were stereotacti-
cally transplanted into the right frontal lobe (2.6 mm lat-
eral and 1.2 mm anterior to bregma, at 5.0 mm depth
from the skull base) via a Hamilton syringe (Hamilton
Company, Reno, NV, USA) using a microinfusion pump
(Harvard Apparatus, Holliston, MA, USA).
ELISA for Expressed BDNF
To investigate the persistence of transgene expression in
vitro, hUCB-MSCs were transfected with pEGFP-BDNF
by MicroPorator™. Culture supernatants were harvested,
fresh medium (α-MEM containing 10% FBS) was added,
and secreted BDNF was assessed at various time inter-
vals. To investigate the persistence of BDNF expression in
vivo, brain tissues (2 mm segment centered on the injec-
tion site) were harvested and lysed in a RIPA buffer at 1,
3, 7, 10, and 14 days after treatment of cells. BDNF pro-
tein secreted into the culture supernatants or brain tis-
sues was analyzed by ELISA assay kits (R&D Systems,
Minneapolis, MN, USA).
Immunophenotyping of hUCB-MSCs
To analyze the cell surface expression of typical marker
proteins in hUCB-MSCs, cells were labeled with the fol-
lowing anti-human antibodies: CD29-PE, CD34-PE,
CD44-PE, CD73-PE, CD90-PE, and HLA-DR-PE (BD
Biosciences). Ten thousand cells were measured using a
FACSCalibur flow cytometer (Becton Dickinson) and the
results were analyzed with CellQuest software (Becton
Dickinson).
Multidifferentiation of Cultured hUCB-MSCs
Differentiation to adipogenic and osteogenic lineages was
induced according to previously described procedures
[2]. After 2-3 weeks of culture, differentiated cells were
fixed with 3% formaldehyde. Adipocytes were detected by
staining the lipid droplets in the cell using 0.3% Oil red-O
staining for 10 min. Osteocytes were detected by calcium
phosphate deposits after von Kossa staining. In brief, cells
were fixed with ethanol and stained with 5% silver nitrate
for 1 hr. After rinsing with distilled water, the cells were
incubated in 5% sodium thiosulfate for 2 min to allow
precipitation of insoluble black silver granules around
calcium phosphate.
Immunocytochemistry
After transfection, cells were fixed with 4% paraformalde-
hyde for 10 min and processed for immunocytochemistry
to identify neural marker-positive cells. Nonspecific anti-
body reactions were blocked with 5% horse serum for 1
hr at room temperature (RT). Next, the fixed cells were
incubated overnight at 4°C with primary antibodies
directed against BDNF (Chemicon, Temecula, CA, USA).
After three washes, cells were incubated with biotinylated
secondary antibodies (Vector Laboratories, Burlingame,
CA, USA) for 1 hr at RT, followed by 1 hr of incubation in
avidin-biotinylated peroxidase complex (Vector Elite Kit,
Vector Laboratories) at RT. Diaminobenzidine (0.05%)
with nickel chloride (0.04%) was used as the chromagen,
and reactions were sustained for 1-6 min at RT. The fixed
cells were then coverslipped with Fluoromount G (South-
ern Biotechnology Associates, Birmingham, AL, UK).
Immunohistochemistry
Rat brains were perfused with PBS followed by 4% para-
formaldehyde under deep anesthesia at 3 days after trans-
plantation of hUCB-MSCs or transfected hUCB-MSCs.
The excised brains were postfixed overnight and then
equilibrated in PBS containing 30% sucrose for 2 days.
Fixed brains were embedded, snap frozen in liquid nitro-
gen, and stored at -70°C until use. Tissues were cryosec-
tioned (16 μm) and then stained with primary antibodies
for anti-BDNF (Chemicon). After three washes, tissues
were incubated with biotinylated secondary antibodies
(Vector Laboratories) for 1 hr at RT, followed by 1 hr of
incubation in avidin-biotinylated peroxidase complex
(Vector Elite Kit, Vector Laboratories) at RT. Vector
NovaRED (Vector Laboratories) was used for visualizing
the immunoreaction products, and reactions were sus-
tained for 1-6 min at RT. Nuclei were counterstained with
Hematoxylin.
In vitro Migration Assay
The migratory ability of hUCB-MSCs was determined
using Transwell plates (Corning Costar, Cambridge, MA,
USA) that were 6.5 mm in diameter with 8 μm pore fil-
ters. 1 × 106 of cells were incubated in 5 ml serum free
MEM for U-87MG or DMEM for astrocytes for 48 hr,
and the resulting conditioned media were used as
chemoattractants. hUCB-MSCs or hUCB-MSCs trans-
fected with pEGFP-N1 (2 × 104) were suspended in 100 μl
serum free medium (SFM) containing 0.1% bovine serum
albumin (Sigma) and seeded into the upper well, and 600
μl of conditioned medium (CM) was placed in the lower
well of the Transwell plate. Following incubation for 5 hr
at 37°C, cells that had not migrated from the upper side of
the filters were scraped off with a cotton swab, and filters
were stained with the three-step stain set (Diff-Quik; Sys-
Lim et al. BMC Biotechnology 2010, 10:38
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to the lower side of the filter was counted under a light
microscope (×200). Experiments were performed in trip-
licate.
Neural Induction Procedure
Neural induction was performed in accordance with the
procedure described by Lim et al. [27]. In brief, cells were
plated in α-MEM containing 10% FBS at 4000 cells/cm2.
Twenty-four hours before induction, the medium was
replaced with a preinduction medium composed of α-
MEM, 10% FBS and 10 ng/ml of basic fibroblast growth
factor (bFGF, Invitrogen). The cells were induced by
replacing the pretreatment medium with neural induc-
tion medium (NIM), consisting of 100 μM butylated
hydroxyanisole (Sigma), 2% dimethylsulfoxide (Sigma),
25 mM KCl, 5 U/ml heparin (Sigma), 20 ng/ml bFGF, 5
μg/ml insulin (Sigma), 100 μg/ml transferring (Sigma), 20
nM progesterone (Sigma), 100 μM putrescine (Sigma), 30
nM sodium selenite (Sigma), and 0.5 μM all-trans-retin-
oic acid (Sigma). After induction, the cells were main-
tained in NIM for up to 7 days.
Western Blot Analysis
Antibodies were obtained from commercial sources:
BDNF, Nestin, βIII tubulin, NeuN, and MBP antibodies
from Chemicon; GFAP antibody from Dako; p-ERKs, and
p-Raf-1 antibodies from New England Biolabs (Ipswich,
MA). For the Western blot analysis, the cells were rinsed
with PBS and subsequently lysed for 30 min on ice in
RIPA-B buffer (0.5% Nonidet P-40, 20 mM Tris, pH 8.0,
50 mM NaCl, 50 mM NaF, 100 μM Na3 VO4, 1 mM DTT,
and 50 μg/ml PMSF). The insoluble material was
removed by centrifugation at 12,000 rpm for 20 min at 48
C. Next, the supernatant was subjected to SDS-PAGE,
and the Western blot analysis was then performed. The
blots were blocked in PBS with 5% skim milk and 0.05%
Tween 20, incubated with the appropriate antibodies and
subsequently incubated with the secondary antibodies
conjugated with horseradish peroxidase. Next, the blots
were assayed using an enhanced chemiluminescence
detection system (Amersham Biosciences, Piscataway NJ,
USA).
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